We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+8.4%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$91.8M
AUM Growth
+$37M
Cap. Flow
+$13.4M
Cap. Flow %
14.65%
Top 10 Hldgs %
67.6%
Holding
39
New
12
Increased
4
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
TWM icon
ProShares UltraShort Russell2000
TWM
+$3.86M
2
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$3.83M
3
AGN
Allergan plc
AGN
+$2.85M
4
QLTI
QLT Inc
QLTI
+$2.32M
5
ADYX
Adynxx Inc
ADYX
+$1.06M

Top Sells

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$951K
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$685K
3
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$642K
4
CPRX
Catalyst Pharmaceutical
CPRX
+$149K
5
IMNN icon
Imunon
IMNN
+$55.7K

Sector Composition

Rank Sector Weight
1 Healthcare 61.46%
2 Miscellaneous 38.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
1
CALL
AstraZeneca
AZN
$255B
$10.3M 11.19%
+150,000
New +$10.4M
AMRI
2
DELISTED
Albany Molecular Research Inc
AMRI
$9.55M 10.4%
542,400
-55,800
-9% -$951K
TWM icon
3
ProShares UltraShort Russell2000
TWM
$44M
$7.12M 7.76%
10,000
+5,000
+100% +$3.86M
AZN icon
4
AstraZeneca
AZN
$255B
$6.84M 7.46%
100,000
– –
TEVA icon
5
Teva Pharmaceuticals
TEVA
$43.8B
$6.23M 6.79%
100,000
– –
DGX icon
6
Quest Diagnostics
DGX
$27B
$5.93M 6.47%
77,208
– –
PFE icon
7
Pfizer
PFE
$160B
$5.22M 5.69%
158,100
– –
LGND icon
8
Ligand Pharmaceuticals
LGND
$5.67B
$3.86M 4.2%
80,150
– –
QLTI
9
DELISTED
QLT Inc
QLTI
$3.57M 3.89%
912,200
+562,200
+161% +$2.32M
BIS icon
10
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$3.45M 3.76%
+12,500
New +$3.83M
SNY icon
11
CALL
Sanofi
SNY
$107B
$3.21M 3.5%
+65,000
New +$3.11M
TEVA icon
12
CALL
Teva Pharmaceuticals
TEVA
$43.8B
$3.12M 3.39%
+50,000
New +$2.91M
AGN
13
DELISTED
Allergan plc
AGN
$2.98M 3.24%
+10,000
New +$2.85M
MNKD icon
14
PUT
MannKind Corp
MNKD
$1.31B
$2.6M 2.83%
+100,000
New +$3.01M
AORT icon
15
Artivion
AORT
$1.3B
$2.29M 2.5%
221,000
+21,000
+11% +$231K
AMRI
16
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$2.11M 2.3%
120,000
– –
SRNE
17
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.45M 1.57%
125,000
-55,479
-31% -$642K
ARIA
18
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.24M 1.35%
150,000
– –
ADYX
19
DELISTED
Adynxx Inc
ADYX
$1.02M 1.11%
+3,267
New +$1.06M
SEEL
20
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
BIS icon
21
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$863K 0.94%
+3,125
New +$956K
ARIA
22
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$824K 0.9%
100,000
– –
FCSC
23
DELISTED
Fibrocell Science Inc.
FCSC
$712K 0.78%
10,518
– –
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
$685K 0.75%
+62,500
New +$707K
CYTK icon
25
Cytokinetics
CYTK
$10.8B
$678K 0.74%
100,000
– –
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Healthcare Value Capital held 39 positions worth $91.8M, up 68% from $54.7M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Healthcare Value Capital deployed $13.4M of net new capital in Q1 2015, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was ProShares UltraShort NASDAQ Biotechnology: 12,500 shares worth $3.45M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 83% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Albany Molecular Research Inc, an estimated $951K trimmed.

  • Healthcare Value Capital's largest Q1 2015 buy was ProShares UltraShort NASDAQ Biotechnology: 12,500 shares worth $3.45M.
  • Healthcare Value Capital added most to ProShares UltraShort Russell2000 in Q1 2015, an estimated $3.86M increase.
  • Healthcare Value Capital's biggest Q1 2015 reduction was Albany Molecular Research Inc, cutting an estimated $951K.
  • Healthcare Value Capital fully exited Catalyst Pharmaceutical in Q1 2015, selling an estimated $149K.
  • Healthcare Value Capital's ten largest holdings make up 68% of its $91.8M portfolio in Q1 2015.
  • Healthcare Value Capital opened 12 new positions and closed 3 in Q1 2015.
  • Healthcare Value Capital's portfolio value rose 68% quarter-over-quarter to $91.8M.

Based on Healthcare Value Capital's 13F filing for Q1 2015, filed 14 May 2015.